International Journal of Antimicrobial Agents
Volume 35, Issue 4 , Pages 375-381, April 2010

Patterns of antimicrobial therapy in severe nosocomial infections: empiric choices, proportion of appropriate therapy, and adaptation rates—a multicentre, observational survey in critically ill patients

  • Dirk Vogelaers

      Affiliations

    • General Internal Medicine & Infectious Diseases, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium
  • ,
  • David De Bels

      Affiliations

    • Intensive Care Department, Brugmann University Hospital, Brussels, Belgium
  • ,
  • Frédéric Forêt

      Affiliations

    • Department of Internal Medicine – Intensive Care Unit, CHR St. Joseph-Warquignies, Boussu, Belgium
  • ,
  • Sophie Cran

      Affiliations

    • Intensive Care Department, CHIREC, Brussels, Belgium
  • ,
  • Eric Gilbert

      Affiliations

    • Intensive Care Department, CHR du Tournaisis, Tournai, Belgium
  • ,
  • Karen Schoonheydt

      Affiliations

    • Intensive Care Department, Ziekenhuisnetwerk Antwerpen, Antwerp, Belgium
  • ,
  • Stijn Blot

      Affiliations

    • General Internal Medicine & Infectious Diseases, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium
    • Corresponding Author InformationCorresponding author. Tel.: +32 9 332 62 16.
  • ,
  • for the ANTHICUS Study Investigators

      Affiliations

    • The ANTHICUS Study Investigators are: O. Abid (RHMS, Ath, Belgium), S. Cran (CHIREC, Brussels, Belgium), D. De Bels (CHU Brugmann, Brussels, Belgium), F. De Leener (CHR St. joseph-Warquignies, Boussu, Belgium), L. Finianos (Clinique St. Joseph, Liège, Belgium), F. Forêt (CHR St. Joseph-Warquignies, Mons, Belgium), M. Genard (CIU Ambroise Paré, Mons, Belgium), E. Gilbert (CHR du Tournaisis, Tournai, Belgium), E. Khodadadi (IRIS Sud-Bracops, Brussels, Belgium), S. Machayekhi (CH Hornu Frameries, Hornu), D. Mircev (IRIS Sud-Etterbeek-Ixelles, Brussels, Belgium), D. Neuberg (CH de L’Ardenne, Libramont, Belgium), J.-Y. Piette (CH Bois de l’Abbaye, Seraign, Belgium), P. Serpe (CH ND Bruyères, Chenee, Belgium), F. Beernaert (H. Hart Ziekenhuis, Eeklo, Belgium), K. De Decker (Antwerp University Hospital, Antwerp, Belgium), K. De Ridder (AZ Maria Middelares, Sint-Niklaas, Belgium), C. Declercq (St. Josef Ziekenhuis, Izegem, Belgium), I. Demeyer (OLV Aalst, Aalst, Belgium), B. Nonneman (ASZ, Aalst, Belgium), K. Schoonheydt (ZNA, Antwerp, Belgium, W. Swinnen (AZ St. Blasius, Dendermonde, Belgium), and L. Wosteyn (ASZ, Roeselaere, Belgium).

Received 17 September 2009; accepted 23 November 2009. published online 01 February 2010.

Abstract 

This prospective, observational multicentre (n=24) study investigated relationships between antimicrobial choices and rates of empiric appropriate or adequate therapy, and subsequent adaptation of therapy in 171 ICU patients with severe nosocomial infections. Appropriate antibiotic therapy was defined as in vitro susceptibility of the causative pathogen and clinical response to the agent administered. In non-microbiologically documented infections, therapy was considered adequate in the case of favourable clinical response <5 days. Patients had pneumonia (n=127; 66 ventilator-associated), intra-abdominal infection (n=23), and bloodstream infection (n=21). Predominant pathogens were Pseudomonas aeruginosa (n=29) Escherichia coli (n=26), Staphylococcus aureus (n=22), and Enterobacter aerogenes (n=21). In 49.6% of infections multidrug-resistant (MDR) bacteria were involved, mostly extended-spectrum β-lactamase (EBSL)-producing Enterobacteriaceae and MDR non-fermenting Gram-negative bacteria. Prior antibiotic exposure and hospitalisation in a general ward prior to ICU admission were risk factors for MDR. Empiric therapy was appropriate/adequate in 63.7% of cases. Empiric schemes were classified according to coverage of (i) ESBL-producing Enterobacteriaceae and non-fermenting Gram-negative bacteria (“meropenem-based”), (ii) non-fermenting Gram-negative bacteria (schemes with an antipseudomonal agent), and (iii) first-line agents not covering ESBL-Enterobacteriaceae nor non-fermenting Gram-negative bacteria. Meropenem-based schemes allowed for significantly higher rates of appropriate/adequate therapy (p<0.001). This benefit remained when only patients without risk factors for MDR were considered (p=0.021). In 106 patients (61%) empiric therapy was modified: in 60 cases following initial inappropriate/inadequate therapy, in 46 patients in order to refine empiric therapy. In this study reflecting real-life practice, first-line use of meropenem provided significantly higher rates of the appropriate/adequate therapy, irrespective of presence of risk factors for MDR.

Keywords: Antibiotic resistance, Multidrug resistance, Intensive care, Infection, Appropriate therapy

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0924-8579(09)00549-4

doi:10.1016/j.ijantimicag.2009.11.015

International Journal of Antimicrobial Agents
Volume 35, Issue 4 , Pages 375-381, April 2010